Full video transcriptClick to expand
Auto-generated transcript of @juanczunigajr's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:00Oh, if I was skinny fat, this is exactly the stack I would run.
- 0:02Your skinny fat.
- 0:03I know you see me there.
- 0:05This is a stack you need.
- 0:06You're not overweight and you're still fit in your jeans.
- 0:09But you have stubborn midsection fat
- 0:10that just doesn't go away.
- 0:12The worst part is you barely even eat.
- 0:13Before I give you my list,
- 0:14I know you the first thing you're gonna pop into your head
- 0:16is red.
- 0:17Red is great, but that's a predictable one.
- 0:19Everybody's heard of it.
- 0:19And right now we're talking about that stubborn fat
- 0:22that just doesn't go away.
- 0:23I'm with red out, if you're already skinny
- 0:25and you misuse it, you're gonna lose strength.
- 0:27And we don't want that.
- 0:27The first one is mat's seat.
- 0:29The reason that you're holding fat
- 0:30is not because you're lazy or eating too much.
- 0:32But it's because your body isn't processing energy.
- 0:34Correct?
- 0:35Mat's seat helps you with that
- 0:36by fixing your insulin sensitivity
- 0:38and gets your metabolism working.
- 0:39You gotta fix that before you see results anywhere else.
- 0:42One is tesamarrelin.
- 0:43The beauty of this one is FDA approved.
- 0:45I love you guys that want FDA approved peptides.
- 0:47This is one of theirs clinical trials
- 0:49showing how it works and how it works on stubborn fat.
- 0:52The benefit of tesamarrelin
- 0:53is that you get better sleep, get better recovery.
- 0:55Your body actually starts changing shape
- 0:57to something you can actually lift with.
- 0:59Everyone's gonna be SLU, PP332.
- 1:03This one works at a cellular level.
- 1:04It makes what exercise does to your metabolism.
- 1:07If you're training, is it where it needs to be yet?
- 1:09It bridges the gap.
- 1:10Why will you build that habit?
- 1:12Is that value fat starts melting away?
- 1:14You add GHK-Cu.
- 1:15It's gonna tie everything up so you look amazing.
Can peptides actually fix 'skinny fat' body composition?
Quick answer
The video targets normal-weight individuals with visceral adiposity and frames the condition as primarily a metabolic processing failure. Two of the four recommended peptides (SLU-PP-332 and MOTS-c) lack any human clinical trial data, while tesamorelin carries FDA approval only for HIV-associated lipodystrophy, not general fat loss. Stacking compounds with unknown human pharmacokinetics and no established safety interactions represents a significant clinical risk that the video does not disclose.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 12 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Can peptides actually fix 'skinny fat' body composition?, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
EGRIFTA (tesamorelin for injection) FDA Prescribing Information
FDA-approved label for tesamorelin (NDA 022505), indicated to reduce excess abdominal fat in HIV patients with lipodystrophy.
FDA
Egrifta (tesamorelin) Original NDA 022505 FDA Approval Letter
FDA approval letter marking the first approved drug for HIV-associated lipodystrophy.
FDA
The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance
Foundational preclinical study (Cell Metabolism) where MOTS-c prevented diet-induced obesity and insulin resistance in mice; no human data.
PubMed
MOTS-c: A novel mitochondrial-derived peptide regulating muscle and fat metabolism
Review summarizing MOTS-c metabolic effects drawn from rodent and cell studies, not human trials.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Can peptides actually fix 'skinny fat' body composition? is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.
Helpful context before the funnel
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "Can peptides actually fix 'skinny fat' body composition?" from Juan Zuniga. We read the clip as a Peptide social video fact-checks claim about Peptide social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: The video targets normal-weight individuals with visceral adiposity and frames the condition as primarily a metabolic processing failure.
The reason this review is not generic is the source wording and the canonical claim label "peptides if you are skinny fat use these peptides to fix it." In this clip, the useful excerpt is: "Oh, if I was skinny fat, this is exactly the stack I would run." That wording changes the review because it points to Peptide social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.
The source trail for this page is checked against EGRIFTA (tesamorelin for injection) FDA Prescribing Information (2024), Egrifta (tesamorelin) Original NDA 022505 FDA Approval Letter (2010), and Effects of tesamorelin in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial (2010), plus the creator's own wording. Peptide social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
The video targets normal-weight individuals with visceral adiposity and frames the condition as primarily a metabolic processing failure.
FormBlends verdict
Peptide social video fact-checks evidence, safety, and patient-fit context
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- The video targets normal-weight individuals with visceral adiposity and frames the condition as primarily a metabolic processing failure. Two of the four recommended peptides (SLU-PP-332 and MOTS-c) lack any human clinical trial data, while tesamorelin carries FDA approval only for HIV-associated lipodystrophy, not general fat loss. Stacking compounds with unknown human pharmacokinetics and no established safety interactions represents a significant clinical risk that the video does not disclose.
- SLU-PP-332 has zero human clinical trials. Every claim about its effects in people is extrapolated from mouse studies published in 2023.
- Tesamorelin's FDA approval covers one specific condition: HIV-associated lipodystrophy. That approval does not extend to healthy individuals seeking fat loss.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- SLU-PP-332 has zero human clinical trials. Every claim about its effects in people is extrapolated from mouse studies published in 2023.
- Tesamorelin's FDA approval covers one specific condition: HIV-associated lipodystrophy. That approval does not extend to healthy individuals seeking fat loss.
- MOTS-c human data exists but is limited to small pilot studies. The 2021 Reynolds et al. Nature Communications trial had preliminary findings and cannot support a broad metabolic optimization claim.
- Normal-weight obesity is a clinically recognized phenotype associated with insulin resistance and cardiovascular risk, so the underlying premise of the video is medically grounded even if the solutions are not.
- Stacking multiple peptides with uncharacterized human safety profiles creates drug interaction risks that no current literature can reliably predict.
- GHK-Cu is legitimate for skin and wound applications, but systemic body composition effects when injected have not been established in controlled human trials.
- Anyone considering peptide therapy for metabolic or body composition goals should have baseline labs including fasting insulin, HbA1c, and DEXA body composition reviewed by a licensed clinician before starting.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What did @juanczunigajr actually say?
The creator pitched a four-peptide stack aimed at people who are "skinny fat," meaning they have a normal body weight but carry stubborn midsection fat. The logic: your body "isn't processing energy correctly," so you need compounds that fix insulin sensitivity, target visceral fat, mimic exercise at a cellular level, and then tie it all together aesthetically. The stack, in order: MOTS-c, tesamorelin, SLU-PP-332, and GHK-Cu. They also briefly dismissed semaglutide ("red") as too aggressive for someone who is already lean, warning it could cost you muscle mass. That last point, at least, has some merit worth examining.
Does the science back this up?
Partially, and the devil is in the details. Tesamorelin is the only compound here with FDA approval, and that approval is specifically for HIV-associated lipodystrophy, not general body recomposition. Extrapolating that to a healthy person with soft midsection fat is a significant leap. MOTS-c research is genuinely interesting but almost entirely preclinical. SLU-PP-332 has never been tested in humans at all. GHK-Cu has skin and wound-healing data but calling it a body composition tool is a stretch.
- MOTS-c: Lee et al. (2015, Cell Metabolism) showed improved insulin sensitivity and reduced obesity in mice. A 2021 human pilot by Reynolds et al. (Nature Communications) suggested metabolic benefits in older adults, but sample sizes were small and results were preliminary.
- Tesamorelin: Falutz et al. (2010, Journal of Clinical Endocrinology and Metabolism) confirmed visceral fat reduction in HIV patients. Off-label use in metabolically healthy people lacks equivalent trial data.
- SLU-PP-332: Zuercher et al. (2023, Journal of Medicinal Chemistry) showed this ERR agonist improved endurance and metabolic markers in mice. Zero human trials exist.
- GHK-Cu: Pickart and Margolina (2018, Biomolecules) reviewed its wound healing and anti-inflammatory properties. No body composition data in humans.
What did they get wrong (or right)?
They got the semaglutide critique roughly right. If you are already lean and use a GLP-1 agonist aggressively without adequate protein and resistance training, muscle loss is a documented risk. Wilding et al. (2021, NEJM) showed meaningful lean mass reduction alongside fat loss in the STEP-1 trial. That caution is fair. What they got wrong is framing SLU-PP-332 as something you can just "run." This compound has no human pharmacokinetic data, no established safety profile, and no dosing literature outside rodent studies. Describing it casually alongside an FDA-approved drug without that disclaimer is misleading. They also said tesamorelin gives "better sleep" and "better recovery," neither of which appears in the FDA label or primary trial endpoints. Those are extrapolated growth hormone class effects, not tesamorelin-specific findings.
What should you actually know?
"Skinny fat," or normal-weight obesity, is a real metabolic phenotype with real health implications. Visceral adiposity in lean individuals correlates with insulin resistance and cardiovascular risk independent of BMI (Ruderman et al., 1998, American Journal of Clinical Nutrition). That part of the premise is legitimate. The problem is the leap from a real condition to a four-compound peptide stack, two of which have no human safety data. Tesamorelin requires a prescription and physician oversight. MOTS-c and SLU-PP-332 are not approved for any use in humans. GHK-Cu is widely available in cosmetics but its systemic effects when injected are poorly characterized. Anyone considering peptide therapy for body composition should be working with a licensed clinician who can assess metabolic labs, not following a TikTok stack recommendation.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Juan Zuniga · TikTok creator
186.4K views on this video
If you are skinny fat use these peptides to fix it
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about slu-pp-332 has zero human clinical trials. every claim about its?
SLU-PP-332 has zero human clinical trials. Every claim about its effects in people is extrapolated from mouse studies published in 2023.
What does the video say about tesamorelin's fda approval covers one specific condition: hiv-associated lipodystrophy. that?
Tesamorelin's FDA approval covers one specific condition: HIV-associated lipodystrophy. That approval does not extend to healthy individuals seeking fat loss.
What does the video say about mots-c human data exists?
MOTS-c human data exists but is limited to small pilot studies. The 2021 Reynolds et al. Nature Communications trial had preliminary findings and cannot support a broad metabolic optimization claim.
What does the video say about normal-weight obesity?
Normal-weight obesity is a clinically recognized phenotype associated with insulin resistance and cardiovascular risk, so the underlying premise of the video is medically grounded even if the solutions are not.
What does the video say about stacking multiple peptides with uncharacterized human safety profiles creates drug?
Stacking multiple peptides with uncharacterized human safety profiles creates drug interaction risks that no current literature can reliably predict.
What does the video say about ghk-cu?
GHK-Cu is legitimate for skin and wound applications, but systemic body composition effects when injected have not been established in controlled human trials.
Sources & references
- [1]Lee et al. (2015)
- [2]Falutz et al. (2010)
- [3]Zuercher et al. (2023)
- [4]Wilding et al. (2021)
- [5]Ruderman et al., 1998
- [6]Pickart and Margolina (2018)
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Juan Zuniga, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.